Methotrexate Use and Monitoring in Patients with Psoriasis: A Consensus Report Based on a Danish Expert Meeting

Line Raaby; Claus Zachariae; Monika Østensen; Lene Heickendorff; Peter Thielsen; Henning Grønbæk; Lone Skov; Nini Kyvsgaard; Jakob T Madsen; Michael Heidenheim; Anne T Funding; Gitte Strauss; Rune Lindberg; Lars Iversen

doi:10.2340/00015555-2599

Methotrexate Use and Monitoring in Patients with Psoriasis: A Consensus Report Based on a Danish Expert Meeting

Line Raaby, Claus Zachariae, Monika Østensen, Lene Heickendorff, Peter Thielsen, Henning Grønbæk, Lone Skov, Nini Kyvsgaard, Jakob T Madsen, Michael Heidenheim, Anne T Funding, Gitte Strauss, Rune Lindberg, Lars Iversen

Institut for Klinisk Medicin

25 Citationer (Scopus)

96 Downloads (Pure)

Abstract

Methotrexate (MTX) has been used in the treatment of psoriasis and other dermatological diseases for more than 50 years. However, there is limited evidence regarding its effect, dose and monitoring, and a lack of consensus regarding how the drug should be used in daily practice. Although the use of MTX is governed by guidelines, such as the European S3-Guidelines and the National Institute for Health and Care Excellence (NICE) guideline, it is important to discuss and adjust these guidelines to national standards. An expert meeting was held in Denmark at the end of 2014, in order to reach consensus regarding the use of MTX in dermatological practice in Denmark. Participants included dermatologists, hepatologists, paediatricians, clinical biochemists and a rheumatologist. Topics discussed were: liver disease monitoring, teratogenic effects of MTX, risk of cancer, and use of MTX in children. We report here the conclusions of this expert meeting regarding use of MTX in dermatological practice.

Originalsprog	Engelsk
Tidsskrift	Acta Dermatovenereologica
Vol/bind	97
Udgave nummer	4
Sider (fra-til)	426-432
ISSN	0001-5555
DOI	https://doi.org/10.2340/00015555-2599
Status	Udgivet - 2017

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.2340/00015555-2599Licens: CC BY-NC

Methotrexate Use and Monitoring in Patients with Psoriasis: A Consensus Report Based on a Danish Expert MeetingForlagets udgivne version, 668 KBLicens: CC BY-NC

Citationsformater

Raaby, L., Zachariae, C., Østensen, M., Heickendorff, L., Thielsen, P., Grønbæk, H., Skov, L., Kyvsgaard, N., Madsen, J. T., Heidenheim, M., Funding, A. T., Strauss, G., Lindberg, R., & Iversen, L. (2017). Methotrexate Use and Monitoring in Patients with Psoriasis: A Consensus Report Based on a Danish Expert Meeting. Acta Dermatovenereologica, 97(4), 426-432. https://doi.org/10.2340/00015555-2599

Raaby, L, Zachariae, C, Østensen, M, Heickendorff, L, Thielsen, P, Grønbæk, H, Skov, L, Kyvsgaard, N, Madsen, JT, Heidenheim, M, Funding, AT, Strauss, G, Lindberg, R & Iversen, L 2017, 'Methotrexate Use and Monitoring in Patients with Psoriasis: A Consensus Report Based on a Danish Expert Meeting', Acta Dermatovenereologica, bind 97, nr. 4, s. 426-432. https://doi.org/10.2340/00015555-2599

@inproceedings{fc588b61b7c84d248c93eb7666086e9a,

title = "Methotrexate Use and Monitoring in Patients with Psoriasis: A Consensus Report Based on a Danish Expert Meeting",

abstract = "Methotrexate (MTX) has been used in the treatment of psoriasis and other dermatological diseases for more than 50 years. However, there is limited evidence regarding its effect, dose and monitoring, and a lack of consensus regarding how the drug should be used in daily practice. Although the use of MTX is governed by guidelines, such as the European S3-Guidelines and the National Institute for Health and Care Excellence (NICE) guideline, it is important to discuss and adjust these guidelines to national standards. An expert meeting was held in Denmark at the end of 2014, in order to reach consensus regarding the use of MTX in dermatological practice in Denmark. Participants included dermatologists, hepatologists, paediatricians, clinical biochemists and a rheumatologist. Topics discussed were: liver disease monitoring, teratogenic effects of MTX, risk of cancer, and use of MTX in children. We report here the conclusions of this expert meeting regarding use of MTX in dermatological practice.",

author = "Line Raaby and Claus Zachariae and Monika {\O}stensen and Lene Heickendorff and Peter Thielsen and Henning Gr{\o}nb{\ae}k and Lone Skov and Nini Kyvsgaard and Madsen, {Jakob T} and Michael Heidenheim and Funding, {Anne T} and Gitte Strauss and Rune Lindberg and Lars Iversen",

year = "2017",

doi = "10.2340/00015555-2599",

language = "English",

volume = "97",

pages = "426--432",

journal = "Acta Dermato-Venereologica",

issn = "0001-5555",

publisher = "Society for the Publication of Acta Dermato - Venereologica",

number = "4",

}

TY - GEN

T1 - Methotrexate Use and Monitoring in Patients with Psoriasis

T2 - A Consensus Report Based on a Danish Expert Meeting

AU - Raaby, Line

AU - Zachariae, Claus

AU - Østensen, Monika

AU - Heickendorff, Lene

AU - Thielsen, Peter

AU - Grønbæk, Henning

AU - Skov, Lone

AU - Kyvsgaard, Nini

AU - Madsen, Jakob T

AU - Heidenheim, Michael

AU - Funding, Anne T

AU - Strauss, Gitte

AU - Lindberg, Rune

AU - Iversen, Lars

PY - 2017

Y1 - 2017

N2 - Methotrexate (MTX) has been used in the treatment of psoriasis and other dermatological diseases for more than 50 years. However, there is limited evidence regarding its effect, dose and monitoring, and a lack of consensus regarding how the drug should be used in daily practice. Although the use of MTX is governed by guidelines, such as the European S3-Guidelines and the National Institute for Health and Care Excellence (NICE) guideline, it is important to discuss and adjust these guidelines to national standards. An expert meeting was held in Denmark at the end of 2014, in order to reach consensus regarding the use of MTX in dermatological practice in Denmark. Participants included dermatologists, hepatologists, paediatricians, clinical biochemists and a rheumatologist. Topics discussed were: liver disease monitoring, teratogenic effects of MTX, risk of cancer, and use of MTX in children. We report here the conclusions of this expert meeting regarding use of MTX in dermatological practice.

AB - Methotrexate (MTX) has been used in the treatment of psoriasis and other dermatological diseases for more than 50 years. However, there is limited evidence regarding its effect, dose and monitoring, and a lack of consensus regarding how the drug should be used in daily practice. Although the use of MTX is governed by guidelines, such as the European S3-Guidelines and the National Institute for Health and Care Excellence (NICE) guideline, it is important to discuss and adjust these guidelines to national standards. An expert meeting was held in Denmark at the end of 2014, in order to reach consensus regarding the use of MTX in dermatological practice in Denmark. Participants included dermatologists, hepatologists, paediatricians, clinical biochemists and a rheumatologist. Topics discussed were: liver disease monitoring, teratogenic effects of MTX, risk of cancer, and use of MTX in children. We report here the conclusions of this expert meeting regarding use of MTX in dermatological practice.

U2 - 10.2340/00015555-2599

DO - 10.2340/00015555-2599

M3 - Conference article

C2 - 27958611

SN - 0001-5555

VL - 97

SP - 426

EP - 432

JO - Acta Dermato-Venereologica

JF - Acta Dermato-Venereologica

IS - 4

ER -

Methotrexate Use and Monitoring in Patients with Psoriasis: A Consensus Report Based on a Danish Expert Meeting

Abstract

FN’s Verdensmål

Adgang til dokumentet

Fingeraftryk

Citationsformater